Trial Profile
A Study to Evaluate the Relative Bioavailability of Five Different Oral Formulations of GSK2251052 and the Multiple-dose, Safety, Tolerability, and Pharmacokinetics of GSK2251052 With and Without Food in Male and Female, Young and Elderly Healthy Volunteers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Sep 2023
Price :
$35
*
At a glance
- Drugs Epetraborole (Primary)
- Indications Gram-negative infections
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 18 Oct 2012 New trial record